Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma

被引：0
|
作者：
Gil-Fernandez, Juan Jose [1 ,2 ]
Ramirez, Patricia Garcia [1 ]
Charavia, Marta Callejas [1 ]
机构：
[1] Univ Hosp Principe Asturias, Hematol Dept, Alcala De Henares, Spain
[2] Univ Hosp Principe Asturias, Hematol Dept, HU Principe Asturias, Madrid 28805, Spain
来源：
CLINICAL CASE REPORTS | 2024年 / 12卷 / 01期
关键词：
daratumumab-refractory myeloma; first-line therapy; isatuximab post daratumumab; newly diagnosed multiple myeloma;
D O I：
10.1002/ccr3.8449
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
    Rodriguez-Otero, Paula
    Moreau, Philippe
    Dimopoulos, Meletios Athanasios
    Beksac, Meral
    Perrot, Aurore
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    van de Donk, Niels W. C. J.
    Schjesvold, Fredrik
    Delforge, Michel
    Einsele, Hermann
    Spencer, Andrew
    Lonergan, Sarah
    Vieyra, Diego
    Sitthi-Amorn, Anna
    Carson, Robin L.
    Blade, Joan
    Boccadoro, Mario
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study
    Landgren, Ola
    Siegel, David S.
    Auclair, Daniel
    Chari, Ajai
    Boedigheimer, Michael
    Welliver, Tim
    Mezzi, Khalid
    Iskander, Karim
    Jakubowiak, Andrzej
    BLOOD, 2018, 132
  • [43] Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Piedra, Katrina
    Peterson, Tim
    Tan, Carlyn
    Orozco, Jennifer
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Lesokhin, Alexander
    Shah, Urvi
    Lu, Sydney
    Patel, Dhwani
    Derkach, Andriy
    Wilkins, Cy R.
    Korde, Neha
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 105 - 109
  • [44] Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma
    Leypoldt, Lisa B.
    Tichy, Diana
    Besemer, Britta
    Hanel, Mathias
    Raab, Marc S.
    Mann, Christoph
    Munder, Markus
    Reinhardt, Hans Christian
    Nogai, Axel
    Gorner, Martin
    Ko, Yon-Dschun
    de Wit, Maike
    Salwender, Hans
    Scheid, Christof
    Graeven, Ullrich
    Peceny, Rudolf
    Staib, Peter
    Dieing, Annette
    Einsele, Hermann
    Jauch, Anna
    Hundemer, Michael
    Zago, Manola
    Pozek, Ema
    Benner, Axel
    Bokemeyer, Carsten
    Goldschmidt, Hartmut
    Weisel, Katja C.
    FUTURE ONCOLOGY, 2024,
  • [45] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
    Nooka, Ajay
    Kaufman, Jonathan
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah
    Anderson, Larry
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas
    Usmani, Saad
    Richardson, Paul
    Voorhees, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156
  • [46] Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial
    Kaiser, Martin F.
    Hall, Andrew
    Smith, Isabelle
    de Tute, Ruth M.
    Roberts, Sadie
    Ingleson, Emma
    Bowles, Kristian M.
    Garg, Mamta
    Lokare, Anand
    Messiou, Christina
    Houlston, Richard S.
    Jackson, Graham
    Cook, Gordon
    Pratt, Guy
    Drayson, Mark T.
    Owen, Roger G.
    Brown, Sarah R.
    Jenner, Matthew W.
    BLOOD, 2022, 140 : 1833 - 1835
  • [47] Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
    Bhutani, Manisha
    Robinson, Myra
    Atrash, Shebli
    Paul, Barry
    Pineda-Roman, Mauricio
    Foureau, David
    Varga, Cindy
    Friend, Reed
    Begic, Xhevahire
    Norek, Sarah
    Drennan, Tiffany
    Anderson, Michelle B.
    Symanowski, James
    Voorhees, Peter M.
    Usmani, Saad Z.
    BLOOD, 2023, 142
  • [48] Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Rodriguez-Otero, Paula
    Hang Quach
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels
    Katodritou, Eirini
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Blade, Joan
    Moreau, Philippe
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S30 - S31
  • [49] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Anderson, Larry D.
    Nathwani, Nitya
    Shah, Nina D.
    Efebera, Yvonne A.
    Costello, Caitlin L.
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2019, 134
  • [50] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
    O'Donnell, Elizabeth K.
    Mo, Clifton C.
    Nadeem, Omar
    Yee, Andrew J.
    Branagan, Andrew R.
    Laubach, Jacob
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette
    Harrington, Cynthia C.
    Agyemang, Emerentia
    Rosenblatt, Jacalyn
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur
    BLOOD, 2022, 140 : 7282 - 7283
12345